Agenda Overview

 

Lisbon, 29 - 31 October 2018

Schedule

Create your personal agenda –check the favourite icon

Oct 2908:40
Conference pass

Opening discussion: Vaccine discovery and challenges in translating research into vaccine products

Keynotes
  • Covering major challenges in translational phase of bench to clinic including scale up challenges and safety for ph1 trials
  • Engaging stakeholders to want to push forward
  • Addressing the scientific roadblocks preventing more vaccines against common and neglected infectious diseases with high mortality rates
  • A new strategy: Can we continue to be dependent on industry for process development and advanced clinical development, especially for products destined for LMICs?
Oct 2909:40
Conference pass

Expectations and reality of cancer vaccines working: The impact of combinational approaches to immune-oncology therapies and more targeted responses

Keynotes
  • Development of novel therapies against cancer, based on vaccines, neoantigens, checkpoint inhibitors and adoptive T cell transfer
  • How close are these to actually treating patients? The translation of innovative therapeutic approaches into early clinical trials
  • Optimal methods of antigen delivery for vaccinesin dendritic cells
Dr Daniel Speiser, Head of Clinical Tumour Biology and Immunotherapy Group, University of LausanneSwitzerland
Professor Dirk Jager, Managing Director, University Hospital of HeidelbergGermany
Dr Laszlo Radvanyi, Senior Vice President, Senior Scientific Advisor, EMD SeronoUnited States
Oct 2911:40
Conference pass

Interactive Roundtables

Keynotes
2 x Interactive Roundtables: 11:40 to 12:25 (rotation one) and 12:25 to 13:10 (rotation two). If you have not filled out the survey please choose them on the sign-up sheets located outside of the exhibition hall/or ask registration for more information. Choose two x 45 min long roundtables for these interactive discussions with like-minded peers
Oct 2911:41
Conference pass

Animal component free media: What’s critical?

Keynotes
To be updated
Oct 2911:41
Conference pass

Applications of CRISPR technology in new global challenges affecting livestock

Keynotes
Dr Christine Tait-Burkard, Assistant Professor, The Roslin InstituteUnited Kingdom
Oct 2911:41
Conference pass

Intradermal delivery of therapeutic vaccines – benefits and challenges

Keynotes
To be updated
Oct 2911:41
Conference pass

New ways of “universalizing” vaccine production: The DiViNe project

Keynotes
Oct 2911:41
Conference pass

Novel uses for classical MMRV vaccine assays in vaccine oncology trials

Keynotes
Oct 2911:41
Conference pass

Safety and regulatory aspects of GMO vaccines

Keynotes
In spite of technological progress towards isolation of pathogen-specific antigens and subsequent production of specific inactivated vaccines, live (attenuated) vaccines may have the simple advantage of having the potency to elicit better and longer-lasting immunity. However, live vaccines tend to have less favourable risk profiles.Both the production of inactivated and live vaccines may involve the application of GMOs, but the actual presence of GMOs in live vaccines places this type of vaccines in an entirely different category, requiring adherence to specific regulations in order to protect patient safety and prevent environmental effects. These and other aspects are of critical relevance for vaccine development and market potential.
Oct 2911:41
Conference pass

Structural vaccinology – the impact on the next generation of vaccines

Keynotes
Dr Arin Ghasparian, CEO, Virometix AGSwitzerland
Oct 2911:41
Conference pass

The regulators relationship with Challenge Studies; yesterday, today & tomorrow

Keynotes
To be updated
Bruno Speder, Head of Clinical Regulatory Affairs, SGS – Life Science ServicesBelgium
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Infection Unit, SGS Life Science ServicesSwitzerland
Oct 2911:41
Conference pass

Vaccine Characterisation and Release – In-vivo vs in-vitro and the use of 3Rs (Reduction, refinement, replacement)

Keynotes
Dr Bassam Hallis, Head of Pre Clinical Development and General Project Manager, Public Health EnglandUnited Kingdom
Oct 2911:41
Conference pass

Vaccine manufacturing process development and production

Keynotes
Moderated bySenior representative, Sartorius
Oct 2914:40
Conference pass

Chair’s opening remarks

Veterinary Vaccines
Oct 2914:45
Conference pass

When will a universal flu vaccines be within reach?

Respiratory Vaccines
Oct 2914:45
Conference pass

Designing effective patient-specific neoantigen cancer vaccines

Immuno-Oncology Profiling
  • Challenges and opportunities in developing a new form of personalized immunotherapy
  • Manufacturing & Clinical updates on Autosynvax™
  • Feasibility of evoking immune responses with reliability and potency
Oct 2914:45
Conference pass

How can ZAPI act as an interface between human and veterinary vaccine development so they can learn from each other?

Veterinary Vaccines
  • Can common requirements be developed and is there a need?
  • The use of novel platform technologies for vaccine production
  • Regulatory innovation for novel vaccine technologies: A 2-stage quality process from veterinary to human vaccines
Dr Jean-Christophe Audonnet, Senior Director, Research Strategy and Key Alliances, Bio R&D and Coordinatior at ZAPI, MerialFrance
Oct 2914:45
Conference pass

Smarter vaccine designs using synthetic virus-like particle technology and structurally optimised antigens

New Vaccine Technology
Oct 2915:00
Conference pass

MVA-VLP as a Plug and Play platform for development of safe and effective single dose vaccines for Emerging Infectious Diseases, Preclinical data for Zika, Ebola and Lassa as examples

New Vaccine Technology
Dr Farshad Guirakhoo, CSO, GeoVax, Inc.United States
Oct 2915:15
Conference pass

Update on the most advanced universal flu vaccine candidate – 6 completed clinical trials

Respiratory Vaccines
Oct 2915:15
Conference pass

Cancer Immunotherapy: Individualized mRNA-based Vaccines for the Treatment of Cancer

Immuno-Oncology Profiling
Oct 2915:15
Conference pass

Comparing naturally acquired immunity to Ebola virus vaccine induced immunity

Hard to Develop Vaccines
Oct 2915:15
Conference pass

Development of a virulence-targeted vaccine to prevent infections caused by MDR bacteria

New Vaccine Technology
Oct 2915:30
Conference pass

Phase IIb trial of a novel influenza vaccine regimen for the over 65s Dr Sarah Gilbert, Professor of Vaccinology, University of Oxford

Respiratory Vaccines
Oct 2915:30
Conference pass
Oct 2915:30
Conference pass

Developments for Tick Borne Encephalitis vaccine

Hard to Develop Vaccines
Prof Roman Prymula, Professor Preventive Medicine, Charles University in PragueCzech Republic
Oct 2915:30
Conference pass

Intranasal adjuvanted vaccines – Inducing mucosal immunity

New Vaccine Technology
Oct 2915:45
Conference pass

Influenza vaccines immunological assessment

Respiratory Vaccines
Reserved for Prof Emanuele Montomolim Chief Scientific Officer, VisMederi Srl & Full Prof. of Public Health, University of Siena
Oct 2915:45
Conference pass

The rationale of combining biomarkers and checkpoint inhibitors with vaccines

Immuno-Oncology Profiling
Oct 2915:45
Conference pass

A new strategy: Latest progress on a Herpes Zoster Vaccine

New Vaccine Technology
Oct 2916:00
Conference pass

Advanced clinical development of a plant-derived quadrivalent VLP vaccine in adults and the elderly

Respiratory Vaccines
Oct 2916:00
Conference pass

Incentivizing industry to develop vaccines for neglected diseases in LMIC

Veterinary Vaccines
Dr Jeremy Salt, Chief Scientific Officer, GalvmedUnited Kingdom
Oct 2916:00
Conference pass

Pseudomonas aeruginosa vaccine development

Hard to Develop Vaccines
Oct 2916:00
Conference pass

Synthetic vaccines to facilitate a rapid response to newly emerging infectious diseases

New Vaccine Technology
Dr Dong Yu, Director and Function Head, GSK VaccinesUnited States
Oct 2916:15
Conference pass

Glioblastoma Immunotherapy (VBI-1901) cancer vaccine update

Immuno-Oncology Profiling
Oct 2916:15
Conference pass

Vaccines against plague

Hard to Develop Vaccines
Ashok Chopra, Distingushed Professor, University of Texas Medical BranchUnited States
Oct 2916:15
Conference pass

mRNA based vaccines and therapeutics for infectious diseases

New Vaccine Technology
Oct 2917:00
Conference pass

RSV F nanoparticle vaccine: Infants via maternal immunization , Ph3 trial update

Respiratory Vaccines
Oct 2917:00
Conference pass

Optimising combination therapies with the aim to enhance immune and clinical responses

Immuno-Oncology Profiling
Dr Daniel Speiser, Head of Clinical Tumour Biology and Immunotherapy Group, University of LausanneSwitzerland
Oct 2917:00
Conference pass

Controlling zoonotic diseases in the developing world

Veterinary Vaccines
Oct 2917:00
Conference pass

New vaccine approaches for older adults: a case study of Shingrix

Hard to Develop Vaccines
Oct 2917:15
Conference pass

Next generation(s) of synthetic glycoconjugate vaccines

New Vaccine Technology
Oct 2917:30
Conference pass

Mucosal vaccination to prevent respiratory diseases – new clinical data of an adjuvanted intranasal influenza vaccine

Respiratory Vaccines
Oct 2917:30
Conference pass

A novel allergen-encoding immunotherapeutic vaccine in the treatment of peanut allergy

Immuno-Oncology Profiling
Professor John Hayball, Professor, University of South AustraliaAustralia
Oct 2917:30
Conference pass

The importance of a One Health approach for biodefense and biosecurity

Veterinary Vaccines
  • Most bioterrorism agents are zoonotic, so how can the human and animal health field work together to achieve global health security-disaster risk reduction?
Oct 2917:30
Conference pass

CEPI supported development of Lassa Fever and MERS vaccines using the Themis MV Platform

New Vaccine Technology
Oct 2917:45
Conference pass

A renewed interest in developing EBV vaccine

Hard to Develop Vaccines
Dr Jeffrey Cohen, Chief of Laboratory of Infectious Diseases, NIHUnited States
Oct 2917:45
Conference pass

CEPI supported vaccine development on Lassa Fever and MERS vaccine development using a DNA platform

New Vaccine Technology

Create your personal agenda –check the favourite icon

Oct 3008:30
Conference pass
Oct 3008:35
Conference pass

Keynote: The role of vaccines, public awareness and industry in preventing further AMR

Keynotes
  • How critical is the risk?
  • Vaccines can’t do it alone – How can we reduce the development of drug resistance?
  • Increasing investment in R&D that meets global public health needs
  • The need for a holistic and collaborative strategy including cross species considerations
Oct 3010:00
Conference pass

Chair’s opening remarks

Veterinary Vaccines
Oct 3010:00
Conference pass

Chair’s opening remarks

Bioprocess, Delivery & Manufacture
Oct 3010:05
Conference pass

Improving the accuracy of tools for personalized medicine- ctDNA

Immuno-Oncology Profiling
Oct 3010:05
Conference pass

Spy and Snoop technologies to accelerate vaccine development

Veterinary Vaccines
- SpyTag, SnoopTag and DogTag are superglues for unbreakable peptide-mediated nano-assembly.- SpyCatcher-linked virus-like particles enable Plug-and-Display vaccine assembly.- Spy-VLPs induce potent antibody responses with potential against challenging human and veterinary targets, including malaria, bacteria and viral pathogens.- Modular vaccine assembly has potential for personalised medicine (e.g. for cancer) and also to accelerate response to outbreaks
Oct 3010:15
Conference pass

Building further on Viroclinics Ferret model with novel insights: Transmission of HRSV in Immunocompromised ferrets

Clinical Development
  • Demonstration of efficient transmission of human respiratory syncytial virus (HRSV) from immunocompromised ferrets to both immunocompromised and immunocompetent ferrets.
  • Research findings were collected by applying several assays including Sequencing, PCR, Virus Culture/Titration. Furthermore, histo pathological changes of respiratory tissues from donor and contact ferrets were demonstrated by standard and immunohistochemistry.
  • A high transmission rate of HRSV was found and more …
Oct 3010:15
Conference pass

What can we do to manage AMR? MRSA, C.diff and E.coli control efforts including Abx practices

Anti-Microbial Resistance
Oct 3010:15
Conference pass

Outer membrane vesicles; A versatile platform for vaccine development

Bioprocess, Delivery & Manufacture
Dr Elly Van Riet, Head of Exploratory and Clinical Research, IntravaccNetherlands
Oct 3010:30
Conference pass

Low-cost, high productivity manufacturing for vector vaccines

Bioprocess, Delivery & Manufacture
Oct 3010:35
Conference pass

The use of genomics in predicting response to immunotherapy

Immuno-Oncology Profiling
Oct 3010:35
Conference pass

Developing vaccines with superior stability

Veterinary Vaccines
  • Why do we need vaccines with improved stability?
  • Use outside the cold chain improves immunisation coverage
  • Is there enough innovation in formulation of vaccines?
  • Conventional approaches to vaccine formulation
  • Innovative formulations to achieve superior vaccine stability
Oct 3010:45
Conference pass

The role of medical informatics in vaccine program design

Clinical Development
Oct 3010:45
Conference pass

Opportunities and challenges for developing vaccines to tackle AMR

Anti-Microbial Resistance
Oct 3010:45
Conference pass

High-density vero cell perfusion culture in packed-bed bioreactors

Bioprocess, Delivery & Manufacture
Dr Joerg (Jörg) Schwinde, Eppendorf Inc.Malaysia
Oct 3012:05
Conference pass

Challenges of assay validation including cell-based format

Clinical Development
Dr Bassam Hallis, Head of Pre Clinical Development and General Project Manager, Public Health EnglandUnited Kingdom
Oct 3012:05
Conference pass

How do we overcome CAR T immunotherapy limitations to enable the treatment of more patients?

Immuno-Oncology Profiling
Oct 3012:05
Conference pass

The transition from research to product development

Veterinary Vaccines
Dr Mel Munro, Project Manager, Biologicals Regulatory Affairs, Triveritas LimitedUnited Kingdom
Oct 3012:05
Conference pass

Why and how the Netherlands maintain one of the lowest AMR rates? What bugs can be stopped by vaccines and which likely are more difficult

Anti-Microbial Resistance
Prof Marc Bonten, Professor, UMC UtrechtNetherlands
Oct 3012:20
Conference pass

Large animal vaccine challenge models and recombinant vaccine technology

Veterinary Vaccines
Oct 3012:20
Conference pass

DiViNe project - Affinity chromatography for vaccines purification

Bioprocess, Delivery & Manufacture
Oct 3012:35
Conference pass

Adjuvants: Their optimal delivery and how they advance into clinical evaluation and assessment of their performance

Clinical Development
Senior representative, Syneos Health
Claire Nguyen Le, Exec Director, Clinical Development, Syneos HealthFrance
Oct 3012:35
Conference pass

Combining Innate and Adaptive Immunity: NK Receptors for CAR T Cell Therapy

Immuno-Oncology Profiling
Oct 3012:35
Conference pass

Yeast-based subunit marker vaccines go multivalent

Veterinary Vaccines
Oct 3012:35
Conference pass

Phasing out broad spectrum antimicrobial use: issues, challenges and potential paths forward?

Anti-Microbial Resistance
The current unnecessary use of broad-spectrum antibiotics results in both microbiome dysbiosis-related health issues and the emergence and spread of antibiotic-resistance traits – and therein set-up the anticipated role of pathogen-targeted antibiotics and antibacterial vaccines in limiting the future emergence and spread of AMR
Dr Anthony Simon Lynch, Senior Scientific Director, Janssen R&DNetherlands
Oct 3012:35
Conference pass

Developing a vaccine manufacturing template for adenovirus vector via a public-private partnership

Bioprocess, Delivery & Manufacture
Oct 3013:05
Conference pass

Clinical development of emerging pathogen vaccines using adenoviral vector platform technology

Clinical Development
Oct 3013:05
Conference pass

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity

Immuno-Oncology Profiling
Dr Peter Timmerman, Chief Scientific Officer, Pepscan TherapeuticsNetherlands
Oct 3013:05
Conference pass

Novel RNA particle vaccine platform for animal health applications

Veterinary Vaccines
Oct 3013:05
Conference pass

Development of a new manufacturing platform technology for human vaccines

Bioprocess, Delivery & Manufacture
Creating scale-down models that can be accurately applied to the commercial scale
Oct 3015:05
Conference pass

Inverse seroconversion following Live Influenza Virus challenge

Clinical Development
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Infection Unit, SGS Life Science ServicesSwitzerland
Oct 3015:05
Conference pass

Priming tumours for immune checkpoint blockade using oncolytic viruses

Immuno-Oncology Profiling
Dr Adel Samson, Lead, Translational Cancer Immunotherapy Group, University of LeedsUnited Kingdom
Oct 3015:05
Conference pass

Innovation milestones in Aqua Health; DNA vaccines

Veterinary Vaccines
  • What is a DNA vaccine, and how do they work?
  • What does it take to bring a new technology into the EU; what hurdles do you face as you prove a new technology is safe and effective?
Oct 3015:05
Conference pass

Reduction of otitis by pneumococcal conjugates

Anti-Microbial Resistance
Oct 3015:05
Conference pass

A proven single-use platform to accelerate the development and production of viral vaccines

Bioprocess, Delivery & Manufacture
Oct 3015:35
Conference pass

Road towards effective control of pertussis: challenges and opportunities

Clinical Development
Dr Dimitri Diavatopoulos, Department of Pediatrics/ Laboratory of Pediatric Infectious Diseases (LPID), Radboud Center for Infectious DiseasesNetherlands
Oct 3015:35
Conference pass

Synergy of DNA Vaccines with checkpoint inhibitors and Standard of Care Agents for Prostate Cancer

Immuno-Oncology Profiling
  • Selection of appropriate vaccine antigens for prostate cancer
  • Updates from ongoing translational trials of DNA vaccines in prostate cancer with anti-PD-1
  • DNA vaccines to augment androgen deprivation therapy
Oct 3015:35
Conference pass

The importance of transboundary and emerging infectious diseases

Veterinary Vaccines
Oct 3015:35
Conference pass

TB, A global problem: One of the biggest bacterial disease burden

Anti-Microbial Resistance
Prof Mark Hatherill, Professor, S.A. Tuberculosis Vaccine InitiativeSouth Africa
Oct 3015:35
Conference pass

Platform manufacturing processes - Designing vaccines for the Global Health need?

Bioprocess, Delivery & Manufacture
Oct 3016:05
Conference pass

A human challenge model of Bordetella pertussis infection, for the testing of novel whooping cough vaccines

Clinical Development
Oct 3016:05
Conference pass

Hope for late-stage ovarian cancer: Development of a personalized dendritic cell vaccine

Immuno-Oncology Profiling
  • Improving dendritic cell platforms
  • Initiating large scale trials and combination therapies
Oct 3016:05
Conference pass

Plasmid launched live attenuated virus vaccines for endemic and epizootic viral livestock diseases

Veterinary Vaccines
Oct 3016:05
Conference pass

Antibody–Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections

Anti-Microbial Resistance
Oct 3016:05
Conference pass

Targeted delivery in rational vaccine design

Bioprocess, Delivery & Manufacture
How physico-chemical properties of liposomes, emulsions, antigens and different routes of delivery can influence the immunological outcome
Oct 3016:35
Conference pass

World Bank collaboration and its capacity for vaccine trials in emerging countries (strategy and plans)

Clinical Development
Oct 3016:35
Conference pass

Targeting IDO positive cells with IO102, an immune modulating vaccine

Immuno-Oncology Profiling
Oct 3016:35
Conference pass

Delivering antigens across the mucosal barrier using nanoparticle-based vaccine formulations

Veterinary Vaccines
Oct 3016:35
Conference pass
Oct 3016:35
Conference pass

Combining intradermal delivery and adjuvants; A new frontier in vaccine enhancement

Bioprocess, Delivery & Manufacture
Elderly persons with comorbidities are at the highest risk of hospitalization for influenza infection and its complications; however, vaccine immunogenicity among these at-risk individuals is suboptimal due to immunosenescence.Various strategies including intradermal vaccination and new vaccine adjuvants have been shown to improve immunogenicity.In this presentation we will give an overview of discrete strategies to improve immune responses (i.e. ID delivery and adjuvants), our own clinical experience, and novel combinations of intradermal delivery and adjuvants that have started to show promise in the clinic.
Oct 3017:05
Conference pass

Challenges in Phase IV studies and register based impact research

Clinical Development
Professor Hanna Nohynek, Deputy Director, National Institute for Health and WelfareFinland
Oct 3017:05
Conference pass

Improving cancer vaccine manufacturing to GMP compatible bioprocesses

Immuno-Oncology Profiling
Oct 3017:05
Conference pass

The future of veterinary vaccine delivery and rethinking vaccination strategies

Veterinary Vaccines
Oct 3017:05
Conference pass

Progress towards developing a prophylactic Vaccine for the prevention of Clostridium difficile infections

Anti-Microbial Resistance

Create your personal agenda –check the favourite icon

Oct 3109:00
Conference pass

Chair’s opening remarks

Veterinary Vaccines
Oct 3109:09
Conference pass

A Case for a (new) Vaccine

A Case for a Vaccine
Where alternative treatments are used, is there a case for a vaccine against the following diseases?
Oct 3109:10
Conference pass

Pre-clinical vaccination success towards the challenge of eliciting HIV envelope glycoprotein-directed broadly neutralizing antibodies (bNAbs)

A Case for a Vaccine
Oct 3109:10
Conference pass

How do we maximize the therapeutic potential of Immuno-oncology through novel combinations?

Immuno-Oncology Profiling
Dr Maria Karasarides, Executive Director, ImmunoOncology, Regeneron PharmaceuticalsUnited States
Oct 3109:10
Conference pass

Looking beyond antibiotics: Time to vaccinate

Veterinary Vaccines
  • How do we encourage increased vaccine usage?
  • Establishing good vaccine practice and compliance
Oct 3109:10
Conference pass

European Commission’s proposal on to strengthened cooperation against vaccine preventable diseases

Vaccine Partnerships
Oct 3109:10
Conference pass

Influenza A and B – Rapid and Precise Antibody-Based Quantification using Sartorius’ Virus Counter 3100

Bioprocess, Delivery & Manufacture
Oct 3109:40
Conference pass

TB vaccine development efforts

A Case for a Vaccine
Professor Helen Mcshane, Professor Of Vaccinology Wellcome Senior Fellow PI Head Of TB Vaccines Group, The Jenner Institute - University of OxfordUnited Kingdom
Oct 3109:40
Conference pass

Rational design of immunotherapy combinations for GI/solid tumour treatment

Immuno-Oncology Profiling
Oct 3109:40
Conference pass

Overcoming the factors hindering the usefulness of veterinary vaccines as alternatives to antibiotics

Veterinary Vaccines
  • Veterinary vaccines can reduce the need for antibiotics, but what factors are currently limiting their usefulness for this?
  • An overview of veterinary vaccinesas antibiotic alternatives today and tomorrow
Oct 3109:40
Conference pass

Interactive panel: External collaborative research and partnering opportunities for vaccine development

Vaccine Partnerships
Oct 3109:40
Conference pass

The plant-based Proficia™ technology: a game changer for influenza vaccine production

Bioprocess, Delivery & Manufacture
Senior representative, Medicago
Oct 3110:10
Conference pass

How can we create a more effective pertussis vaccine?

A Case for a Vaccine
Oct 3110:10
Conference pass

Primate derived adenovectors synergize with immunomodulators for the treatment of established tumors

Immuno-Oncology Profiling
Oct 3110:10
Conference pass

Overcoming the challenges of commercialising the management of the microbiome

Veterinary Vaccines
  • Overview of innovation strategies to manipulate the microbiome and improve livestock productivity
  • How do we commercialise these innovative strategies?
Oct 3110:10
Conference pass

Continuous production of influenza viruses in cell culture and use of continuous downstream processing for purification of virus particles/viral antigens

Bioprocess, Delivery & Manufacture
Reserved for IFPMA
Oct 3111:20
Conference pass

Strategies for global hepatitis C elimination – Do we need a prophylactic vaccine?

A Case for a Vaccine
Dr Michael Manns, Professor, Hannover Medical SchoolGermany
Oct 3111:20
Conference pass

Antibody based combination immunotherapy

Immuno-Oncology Profiling
Oct 3111:20
Conference pass

Developing novel vaccine types to fight mycoplasma infections in livestock

Veterinary Vaccines
Oct 3111:20
Conference pass

The challenges faced during process development and scale-up in Biopharmaceutical and vaccine Industries

Bioprocess, Delivery & Manufacture
Reserved for Serum Institute of India
Oct 3111:50
Conference pass

Fast authorizations of vaccines for emerging diseases

Veterinary Vaccines
Dr Rosario Bullido, Head of Veterinary Inmunological Medicines Assessment Unit Veterinary Medicines Department, AempsSpain
Oct 3111:50
Conference pass

Investor panel: Hear how different investors decide on who and what they invest in, and why

Vaccine Partnerships
Panellists to be announced
Oct 3111:50
Conference pass

Bioprocess engineering of insect cells for enhanced production of VLPs for vaccine development

Bioprocess, Delivery & Manufacture
Oct 3112:20
Conference pass

GAS vaccine efforts

A Case for a Vaccine
Prof Anne Botteaux, Molecular Bacteriology Laboratory, Universite Libre De BruxellesBelgium
Oct 3112:20
Conference pass

Unbiased functional screening of large bispecific antibody panels to unlock novel biology

Immuno-Oncology Profiling
Oct 3112:20
Conference pass

From development to commercialization of vaccines – A case study

Bioprocess, Delivery & Manufacture
Oct 3114:00
Conference pass

Status of vaccine confidence around the world

Keynotes
  • Social and political factors that can affect uptake of vaccines
  • How can we better educate the public the benefits of immunisation?
  • How can public health institutions, government and vaccine developers help with building a coherent story
  • AEFI surveillance and risk communication
  • Are we overlooking the power of social media?
Professor Hanna Nohynek, Deputy Director, National Institute for Health and WelfareFinland
Fred Zepp, Medical Director and Chairman, University Medicine MainzGermany
Prof Roman Prymula, Professor Preventive Medicine, Charles University in PragueCzech Republic
Oct 3114:50
Conference pass

Flumist vaccine effectiveness – It’s return and the real story

Keynotes
  • Questions over the effectiveness of the live attenuated vaccine
  • Why it lost its recommendation
  • The journey, investigation and trial data to rectify this
Dr Helen Bright, Head, Team of Cell and Molecular Biologics, MedImmuneUnited Kingdom
Oct 3115:15
Conference pass

Closing plenary: The future of vaccinology: Incorporating bioinformatics, omics and structural vaccinology into vaccine design

Keynotes
  • A bottleneck for all, the ability to manage and analyze in an integrative with all the data that is generated
  • interpreting everything into something meaningful
last published: 20/Sep/18 12:25 GMT

 

 

DOWNLOAD AGENDA

 

Sign Up for Event Updates